Comparative Pharmacology
Head-to-head clinical analysis: DAYTRANA versus DEXEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYTRANA versus DEXEDRINE.
DAYTRANA vs DEXEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
None Documented
None Documented
Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Category C
Category C
CNS Stimulant
CNS Stimulant